Business

Add as a preferred source on Google

GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tues…

1 min read
EconoTimes — Reading the Times. Understanding the Future.

SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in Monte Carlo, Monaco on Tuesday, April 10 at 9:00 a.m. Central European Time.

The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section.

About GBT
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its lead product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Myesha Lacy (investors)
GBT
650-351-4730
investor@gbt.com 

Julie Normart (media)
W2O pure
415-946-1087
media@gbt.com

Primary Logo

Related articles

View all
Business

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 04, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on May 1, 2018, the compensation committee of the Company’s board of directors granted four new employe…

Business

GBT Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., April 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on April 2, 2018, the compensation committee of the Company’s board of directors granted one new empl…